{"entity":{"id":"lm-108","kind":"drug","name":"LM-108","aka":[],"tldr":"LM-108 is an experimental monoclonal antibody from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer, with its target not yet stated publicly.","summary":"LM-108 is a monoclonal antibody developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and LaNova Medicines. The sponsor describes its target as CCR8, which OnCo does not yet have a target page for. ClinicalTrials.gov describes the intervention as: LM-108 injection is a monoclonal antibody that selectively clears regulatory T cells that infiltrate tumour sites. Penpulimab is a novel and differentiated programmed cell death protein 1 (PD-1) monoclonal antibody. Oxaliplatin is a third-ge. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07362186 (LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma), in pancreatic ductal adenocarcinoma and gastric & gastro-oesophageal junction cancer. The largest, NCT07362186, plans to enrol 400 participants with primary completion expected 2028-08-17. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-3","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of LM-108","url":"https://clinicaltrials.gov/search?intr=LM-108"},{"label":"Sponsor page","url":"https://www.lanovamedicines.com/en"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sino-biopharm","lanova-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07362186","nct05518045"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"monoclonal antibody","mechanism":"Mechanism not stated in the ClinicalTrials.gov record or on the sponsor's pipeline page.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/lm-108/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"lanova-medicines","kind":"company","name":"LaNova Medicines","route":"/companies/lanova-medicines/"},{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct05518045","kind":"trial","name":"A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors","route":"/trials/nct05518045/"},{"id":"nct06387628","kind":"trial","name":"LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer","route":"/trials/nct06387628/"},{"id":"nct07362186","kind":"trial","name":"LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma","route":"/trials/nct07362186/"}]}}